LEGN - 2seventy bio downgraded at Morgan Stanley after Abecma sales
2023-07-28 09:47:07 ET
More on 2seventy bio
- 2seventy bio: Nothing Properly Explains The Low Valuation
- 2seventy bio posts Phase 1 results for CAR-T therapy in bone marrow cancer
- Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expanded use
- 2seventy bio launches $100M stock offering
- Bristol-Myers, 2seventy post late-stage data for CAR-T therapy in multiple myeloma
For further details see:
2seventy bio downgraded at Morgan Stanley after Abecma sales